EMA Authorised: Ezmekly (mirdametinib) — Merck Europe B.V.

View source ↗

Summary

EU authority authorised Ezmekly (mirdametinib) for Neurofibromatosis type 1 with neurofibromas, including plexiform neurofibroma, under conditional and orphan d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibroma
• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Ezmekly (mirdametinib)

Snippet

Status: Authorised. Therapeutic area: Neurofibromatosis 1;Neurofibroma, Plexiform. MAH: Merck Europe B.V.. Decision date: 12/08/2026. Conditional approval. Orphan medicine